Menu Search
Equities

Genetic Signatures Ltd

GSS:ASX

Genetic Signatures Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.71
  • Today's Change0.02 / 2.90%
  • Shares traded19.79k
  • 1 Year change+54.65%
  • Beta-0.3100
Data delayed at least 20 minutes, as of Nov 18 2024 04:05 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Genetic Signatures Ltd's revenues fell -35.29% from 22.06m to 14.27m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 14.05m to a larger loss of 17.86m.
Gross margin44.56%
Net profit margin-125.15%
Operating margin-124.91%
Return on assets-30.70%
Return on equity-34.34%
Return on investment-34.00%
More ▼

Cash flow in AUDView more

In 2024, Genetic Signatures Ltd increased its cash reserves by 121.74%, or 19.90m. Cash Flow from Financing totalled 34.82m or 243.94% of revenues. In addition the company used 10.12m for operations while cash used for investing totalled 4.79m.
Cash flow per share-0.0913
Price/Cash flow per share--
Book value per share0.2838
Tangible book value per share0.2548
More ▼

Balance sheet in AUDView more

Genetic Signatures Ltd uses little debt in its capital structure as supported by a debt to capital ratio of 1.96%.
Current ratio10.04
Quick ratio8.76
Total debt/total equity0.02
Total debt/total capital0.0196
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.